サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Top 30 Pharmaceutical Wholesale & Distribution Organizations 2019

医薬品卸&販社トップ30社2019

レポート概要

医薬品卸、販売市場は活気に溢れ、命を救う医薬品を迅速に大勢の人々に届けています。この市場は大規模で、予測期間中、多くの成長機会があります。医薬品卸市場はメーカーがコアコンピタンスに集中するために医薬品販売を卸事業者に委託したいと望んでいるメーカーによってけん引されてきました。同時に、病院はこの分野への投資を減らすための一環として在庫管理業務を外部に委託しました。これらの要因によって卸、販売サービス全体の需要が増大しました。

このレポートがもたらすメリット

読み進めるにつれてこのセクターに出現するビジネスチャンスを掴む方法が明らかになります。

この253ページのレポートに157の表とグラフを掲載‐これらは全て他のどこでも入手できないものです。

このレポートを利用することによって主要な医薬品卸&販社について明確で詳細な見識を得ることができます。また市場の主な推進要因と課題が明らかになります。

レポート詳細

目次

1. Report Overview
1.1 Global Pharma Wholesale and Distribution Industry and Market Overview
1.2 How This Report Delivers
1.3 Questions Answered by This Analytical Report
1.4 Who is This Report For?
1.5 Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain

2. Introduction to Pharma Wholesale and Distribution
2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
2.1.1 Full-Line Wholesalers (FLWs)
2.1.2 Short-Line Wholesalers (SLWs)
2.2 The Chain of Distribution: Wholesalers vs. Logistic Service Providers
2.2.1 Secondary Wholesalers
2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
2.2.3 Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits
2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
2.2.5 Pharmacy Benefit Managers
2.3 Generative Revenue and Profit
2.3.1 Forward Buying to Avoid Price Increases
2.3.2 Fee-for-Service: A Clear Pricing Structure
2.3.2.1 Inventory Management Agreements
2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
2.3.4 Reimbursement and Wholesalers
2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
2.3.6 Parallel Trade: Different Attitudes in Europe and the US

3. The World Pharmaceutical Wholesale and Distribution Market: 2019-2029
3.1 The World Pharmaceutical Wholesale and Distribution Market in 2018, Restricted by Government Price Reductions and Generic Substitution
3.2 The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2019-2029
3.3 Branded and Generic Drugs: Revenue vs. Profit, 2019-2029
3.3.1 Branded and Generic Drugs: Revenue Generation, 2018
3.3.2 Branded Drugs: Revenue Forecast, 2019-2029
3.3.3 Generic Drugs: Revenue Forecast, 2019-2029

4. Leading Pharma Wholesalers and Distributors In 2018: Current and Future Performance
4.1 McKesson: The Oldest and Largest Healthcare Services Company in the US
4.1.1 McKesson: General Information
4.1.1.1 McKesson, Pharmaceutical Product Category
4.1.1.2 McKesson, Management Member Names
4.1.1.3 McKesson, Sales Structure
4.1.2 McKesson: Historical Performance, 2008-2018
4.1.3 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
4.1.4 McKesson: Revenue Forecast, 2019-2029
4.1.5 McKesson: Strategic Moves & Developments, 2018-2019
4.2 Cardinal Health: The World’s Third Largest Pharma Wholesaler
4.2.1 Cardinal Health: General Information
4.2.1.1 Cardinal Health, Pharmaceutical Product Category
4.2.1.2 Cardinal Health, Sales Structure
4.2.1.3 Cardinal Health, Management Member Names
4.2.2 Cardinal Health: Historical Performance, 2008-2018
4.2.3 Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
4.2.4 Cardinal Health: Revenue Forecast, 2019-2029
4.2.5 Cardinal Health: Strategic Moves & Developments, 2018-2019
4.3 AmerisourceBergen: Third Largest Global Pharma Wholesaler and Distributor
4.3.1 AmerisourceBergen: General Information
4.3.1.1 AmerisourceBergen, Pharmaceutical Product Category
4.3.1.2 AmerisourceBergen: Sales Structure
4.3.1.3 AmerisourceBergen, Management Member Names
4.3.2 AmerisourceBergen: Historical Performance, 2008-2018
4.3.3 Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
4.3.4 AmerisourceBergen: Revenue Forecast, 2019-2029
4.3.5 AmerisourceBergen: Strategic Moves & Developments, 2017-2019
4.4 Walgreens Boots Alliance: The Largest Drugstore Chain in the US and Global Wholesale and Distribution Network
4.4.1 Walgreens Boots Alliance: General Information
4.4.1.1 Walgreens Boots Alliance, Pharmaceutical Product Category and Brands
4.4.1.2 Walgreens Boots Alliance (WBA), Sales Structure
4.4.1.3 Walgreens Boots Alliance, Management Member Names
4.4.2 Walgreens Boots Alliance: Historical Performance, 2011-2018
4.4.3 Acquisitions and Future Strategies of Walgreens Boots Alliance
4.4.4 Walgreens Boots Alliance: Revenue Forecast, 2019-2029
4.4.5 Walgreens Boots Alliance: Strategic Moves & Developments, 2018-2019
4.5 MEDIPAL HOLDINGS CORPORATION: Japan’s Leading Pharmaceutical Wholesaler
4.5.1 MEDIPAL Holdings: General Information
4.5.1.1 MEDIPAL Holdings, Pharmaceutical Product Category
4.5.1.2 MEDIPAL Holdings, Sales Structure
4.5.1.3 MEDIPAL Holdings, Management Member Names
4.5.2 MEDIPAL HOLDINGS CORPORATION: Historical Performance, 2008-2018
4.5.3 Future Strategies of MEDIPAL HOLDINGS CORPORATION: Revised Business Portfolio with Diverse Sources of Earnings
4.5.4 MEDIPAL HOLDINGS CORPORATION: Revenue Forecast, 2019-2029
4.6 Phoenix Group: Biggest European Wholesalers
4.6.1 Phoenix Group: General Information
4.6.1.1 Phoenix Group, Pharmaceutical Product Category
4.6.1.2 Phoenix Group, Sales Structure
4.6.1.3 Phoenix Group, Management Member Names
4.6.2 The PHOENIX Group: Historical Performance, 2011-2018
4.6.3 Future Strategies of the PHOENIX Group: Selective Acquisition
4.6.4 The PHOENIX Group: Revenue Forecast, 2019-2029
4.7 SINOPHARM: The Leading Pharmaceutical Wholesaler and Distributor in China
4.7.1 SINOPHARM: General Information
4.7.1.1 SINOPHARM, Pharmaceutical Product and Business Category
4.7.1.2 SINOPHARM, Sales Structure
4.7.1.3 SINOPHARM, Management Member Names
4.7.2 SINOPHARM: Historical Performance, 2011-2018
4.7.3 Future Strategies of SINOPHARM: Provide Comprehensive Services and Wider Business Coverage
4.7.4 SINOPHARM: Revenue Forecast, 2019-2029
4.8 Alfresa Holdings: Second Largest Pharmaceutical Wholesaler and Distributor in Japan
4.8.1 Alfresa Holdings: General Information
4.8.1.1 Alfresa Holdings, Pharmaceutical Product and Business Category
4.8.1.2 Alfresa Holdings, Sales Structure
4.8.1.3 Alfresa Holdings, Management Member Names
4.8.2 Alfresa Holdings: Historical Performance, 2011-2018
4.8.3 Future Strategy of Alfresa Holdings: To Focus on Expanding Business Fields and Increasing Footprint
4.8.4 Alfresa Holdings: Revenue Forecast, 2019-2029
4.9 SUZUKEN CO., LTD: The First Nationwide Wholesaler of Japan
4.9.1 SUZUKEN CO., LTD: General Information
4.9.1.1 SUZUKEN CO., LTD, Pharmaceutical Product and Business Category
4.9.1.2 SUZUKEN CO., LTD, Sales Structure
4.9.1.3 SUZUKEN CO., LTD, Management Member Names
4.9.2 SUZUKEN CO. LTD: Historical Performance, 2011-2018
4.9.3 Future Strategies of SUZUKEN CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
4.9.4 SUZUKEN CO., LTD: Revenue Forecast, 2019-2029
4.9.5 SUZUKEN: Strategic Moves & Developments, 2018-2019
4.10 Shanghai Pharmaceuticals Holding: China’s Second Largest Wholesaler
4.10.1 Shanghai Pharmaceuticals Holding: General Information
4.10.1.1 Shanghai Pharmaceuticals Holding, Pharmaceutical Product and Business Category
4.10.1.2 Shanghai Pharmaceuticals Holding; Sales Structure
4.10.1.3 Shanghai Pharmaceuticals Holding Management Member Names
4.10.2 Shanghai Pharmaceuticals Holding: Historical Performance, 2011-2018
4.10.3 Future Strategies of Shanghai Pharma: Expansion of Three Leading Regions in China
4.10.4 Shanghai Pharma: Revenue Forecast, 2019-2029
4.11 Morris & Dickson Co. LLC: Serving More than 175 Years
4.12 Smith Drug Company: Serving More than 1400 Customers in U.S.
4.13 Anda Inc.
4.13.1 Segment Overview
4.13.2 Anda Inc. Strategies:
4.14 CuraScript Specialty Distribution
4.14.1 Curascript Speciality Distribution Strategies:
4.15 Mawdsley-Brooks & Co. Ltd.
4.15.1 Mawdsley-Brooks & Co Company History:
4.15.2 Mawdsley-Brooks & Co Company Strategies:
4.16 North Carolina Mutual Wholesale Drug: 65 years of service
4.16.1 Mutual Wholesale Drug Company History:
4.16.2 Company Strategies
4.17 Prodigy Health
4.18 Fortissa Limited: 20 years of vast experience
4.19 CR Pharmaceutical
4.19.1 Company History
4.19.2 Company Strategies
4.20 Hygen Pharmaceuticals Inc.
4.20.1 Hygen Pharmaceuticals Inc.; Key Strategies and achievements:
4.21 Fff Enterprises Inc.
4.21.1 Company Strengths:
4.21.2 Fff Enterprises Inc.Strategies, Development and Achievements:
4.22 Rochester Drug Cooperative
4.23 Auburn Pharmaceutical Company
4.23.1 Generic Product with Launch Dates
4.24 Capital Wholesale Drug Company
4.25 Realcan Pharmaceutical Group Co., Ltd.
4.26 Profarma Distribuidora de Produtos Farmaceuticos SA
4.27 Dakota Drug, Inc.
4.28 Zhejiang Intl Group Co., Ltd.
4.29 Ohki Health Care Holdings, Inc.
4.30 Kingworld Medicines Group Ltd.

5. Qualitative Analysis of The Pharma Wholesale and Distribution Market
5.1 The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2018
5.1.1 The Insatiable Demand for Drugs: A Recession Proof Industry?
5.1.2 Wholesalers Do More than Deliver Drugs
5.1.2.1 Pre-Wholesaling: More Prevalent in Europe
5.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market
5.1.3 Large Companies Dominate the Market
5.1.4 Despite High Revenues, Profit Margins Are Low
5.1.5 Government-Induced Drug Price Pressures Restrict Profits
5.1.6 The Problem of Counterfeit Drugs
5.2 The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2019-2029
5.2.1 The Demand for Pharmaceuticals is Increasing
5.2.2 The Increasing Use of Specialty Drugs Will Drive Growth
5.2.3 The Increasing Use of Generic Drugs Will Limit Revenue, But Drive Profit Generation
5.2.4 The Promotion of Drug Therapy in the US
5.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
5.2.6 Increased Adoption of the DTP Distribution Model
5.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold
5.2.6.2 DTP in the UK Since 1991
5.2.6.3 DTP in Poland: The Second European Country To Adopt the DTP Model
5.2.6.4 Further Expansion of the DTP Model
5.2.7 The Threat of Healthcare Budget Cuts
5.2.7.1 Healthcare Budget Cuts in Germany
5.2.7.2 Healthcare Budget Cuts in France
5.2.7.3 Healthcare Budget Cuts in Italy
5.2.7.4 Healthcare Budget Cuts in Spain
5.2.7.5 Healthcare Budget Cuts in the UK
5.2.8 Do Large Pharmacy Chains Pose a Threat?
5.2.8.1 Case Study: Walmart and the $4 Prescription Scheme
5.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Pharmacy Chains
5.2.9 Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry?
5.2.10 The Threat of Industry Consolidation
5.3 Social, Technological, Economic and Political Factors Influencing the Market, 2018-2029 (STEP Analysis)
5.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
5.3.2 Political Factor: Combating Counterfeit Medicines
5.3.2.1 The US and E-Pedigree: Becoming Law in California
5.3.2.2 European Pedigree Legislation
5.3.2.3 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government is Attempting to Address the Challenge
5.3.2.4 Serialisation for Wholesalers: Opportunity or a Challenge?

6. Conclusions
6.1 The Future of the Pharma Wholesale and Distribution Market
6.2 The Leading National Pharma Wholesale and Distribution Markets
6.3 The Leading Companies in the Pharma Wholesale and Distribution Industry
6.4 Trends in the Pharma Wholesale and Distribution Industry
6.4.1 Generics Will Threaten Revenue
6.4.2 Manufacturers Will Deliver More Drugs Directly
6.4.3 There Will Be Greater Demand for Specialty Medicines
6.4.4 Consolidation Will Drive Growth
6.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers’ Costs

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
TABLE 2.1 USE OF DTP MODEL IN THE UK, 2007-2012
TABLE 3.1 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN), AGR (%), CAGR (%), 2019-2029
TABLE 3.2 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION BY SEGMENT: REVENUE ($BN) FORECASTS, AGR (%), CAGR (%) AND MARKET SHARES (%), 2019-2029
TABLE 3.3 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS: REVENUE ($BN) FORECASTS, AGR (%), CAGR (%), 2019-2029
TABLE 3.4 WHOLESALE AND DISTRIBUTION OF GENERIC DRUGS: REVENUE ($BN) FORECASTS, AGR (%), CAGR (%), 2019-2029
TABLE 4.1 MCKESSON, DISTRIBUTION SOLUTIONS: SERVICES AND CUSTOMERS, 2018
TABLE 4.2 MCKESSON, TECHNOLOGY SOLUTIONS: SERVICES AND CUSTOMERS, 2018
TABLE 4.3 MCKESSON, TECHNOLOGY SOLUTIONS: MANAGEMENT MEMBERS, 2018
TABLE 4.4 MCKESSON: HISTORICAL REVENUE ($BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT ($BN), GROSS PROFIT AGR (%) AND GROSS PROFIT CAGR (%), 2008-2018
TABLE 4.5 MCKESSON REVENUE ($BN), REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
TABLE 4.6 MCKESSON: GROSS PROFIT ($BN), GROSS PROFIT SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
TABLE 4.7 ACQUISITIONS BY MCKESSON, 2007-2018
TABLE 4.8 MCKESSON: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
TABLE 4.9 MCKESSON: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
TABLE 4.10 MCKESSON: STRATEGIC MOVES & DEVELOPMENTS, 2018-2019
TABLE 4.11 CARDINAL HEALTH: MANAGEMENT MEMBERS, 2018
TABLE 4.12 CARDINAL HEALTH: HISTORICAL REVENUE ($BN), REVENUE AGR (%), REVENUE CAGR (%), OPERATING EARNINGS ($BN), AGR (%) AND CAGR (%), 2008-2018
TABLE 4.13 CARDINAL HEALTH: REVENUE ($BN), REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
TABLE 4.14 CARDINAL HEALTH: OPERATING EARNINGS ($BN) AND ANNUAL GROWTH (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
TABLE 4.15 CARDINAL HEALTH: REVENUE ($BN) AND REVENUE SHARE (%) BREAKDOWN BY CUSTOMER, 2018
TABLE 4.16 SELECTED ACQUISITIONS BY CARDINAL HEALTH AND THEIR LINE OF BUSINESS, 2008-2018
TABLE 4.17 CARDINAL HEALTH: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
TABLE 4.18 CARDINAL HEALTH: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
TABLE 4.19 CARDINAL HEALTH: STRATEGIC MOVES & DEVELOPMENTS, 2018-2019
TABLE 4.20 AMERISOURCEBERGEN: MANAGEMENT MEMBERS, 2018
TABLE 4.21 AMERISOURCEBERGEN: HISTORICAL REVENUE ($BN), REVENUE AGR (%), REVENUE CAGR (%), OPERATING INCOME ($BN), OPERATING INCOME AGR (%) AND OPERATING INCOME CAGR (%), 2008-2018
TABLE 4.22 AMERISOURCEBERGEN: REVENUE ($BN), REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
TABLE 4.23 AMERISOURCEBERGEN: GROSS PROFIT ($BN), GROSS PROFIT SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
TABLE 4.24 AMERISOURCEBERGEN: REVENUE ($BN) AND REVENUE SHARE (%) BREAKDOWN BY CUSTOMER, 2018
TABLE 4.25 ACQUISITIONS BY AMERISOURCEBERGEN AND THEIR LINE OF BUSINESS, 2008-2018
TABLE 4.26 AMERISOURCEBERGEN: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
TABLE 4.27 AMERISOURCEBERGEN: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
TABLE 4.28 AMERISOURCEBERGEN: STRATEGIC MOVES & DEVELOPMENTS, 2017-2019
TABLE 4.29 WALGREENS BOOTS ALLIANCE: MANAGEMENT MEMBERS, 2018
TABLE 4.30 WALGREENS BOOTS ALLIANCE: REVENUE ($BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT ($BN), GROSS PROFIT AGR (%) AND GROSS PROFIT CAGR (%), 2011-2018
TABLE 4.31 WALGREENS BOOTS ALLIANCE: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
TABLE 4.32 WALGREENS BOOTS ALLIANCE: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
TABLE 4.33 WALGREENS BOOTS ALLIANCE: STRATEGIC MOVES & DEVELOPMENTS, 2018-2019
TABLE 4.34 MEDIPAL HOLDINGS: CONSOLIDATED SUBSIDIARY COMPANIES, 2016
TABLE 4.35 MEDIPAL HOLDINGS: MANAGEMENT MEMBERS, 2018
TABLE 4.36 MEDIPAL HOLDINGS: HISTORICAL REVENUE (\BN, $BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT AGR (%), 2008-2018
TABLE 4.37 MEDIPAL HOLDINGS: REVENUE (\BN) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2016-2019
TABLE 4.38 MEDIPAL HOLDINGS: OPERATING PROFIT (\BN), AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2017-2018
TABLE 4.39 MEDIPAL HOLDINGS: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
TABLE 4.40 MEDIPAL HOLDINGS: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
TABLE 4.41 PHOENIX GROUP: MANAGEMENT MEMBERS, 2018
TABLE 4.42 PHOENIX GROUP: SUBSIDIARY COMPANIES, 2018
TABLE 4.43 PHOENIX GROUP: HISTORICAL REVENUE (€BN, $BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT (€BN, $BN), GROSS PROFIT AGR (%) AND GROSS PROFIT CAGR (%), 2011-2018
TABLE 4.44 PHOENIX GROUP: REVENUE SHARE (%) BREAKDOWN BY REGION, 2017-2018
TABLE 4.45 PHOENIX GROUP: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
TABLE 4.46 PHOENIX GROUP: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
TABLE 4.47 SINOPHARM: MANAGEMENT MEMBERS, 2018
TABLE 4.48 SINOPHARM GROUP: HISTORICAL REVENUE (RMBBN, $BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT (RMBBN, $BN), GROSS PROFIT AGR (%) AND GROSS PROFIT CAGR (%), 2011-2018
TABLE 4.49 SINOPHARM GROUP: REVENUE (RMBBN, $BN) AND REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2016-2018
TABLE 4.50 SINOPHARM GROUP: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
TABLE 4.51 SINOPHARM GROUP: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
TABLE 4.52 ALFRESA HOLDINGS: LIST OF SIGNIFICANT SUBSIDIARIES AND AFFILIATES, 2018
TABLE 4.53 ALFRESA HOLDINGS: MANAGEMENT MEMBERS, 2018
TABLE 4.54 ALFRESA HOLDINGS: HISTORICAL REVENUE (\BN, $BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT (\BN, $BN), GROSS PROFIT AGR (%) AND GROSS PROFIT CAGR (%), 2011-2018
TABLE 4.55 ALFRESA HOLDINGS: BUSINESS STRATEGIES, 2013-2018
TABLE 4.56 ALFRESA HOLDINGS: REVENUE (\BN, $BN), REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2016-2018
TABLE 4.57 ALFRESA HOLDINGS: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
TABLE 4.58 ALFRESA HOLDINGS: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
TABLE 4.59 SUZUKEN CO., LTD: MANAGEMENT MEMBERS, 2018
TABLE 4.60 SUZUKEN: HISTORICAL REVENUE (\BN, $BN), REVENUE AGR (%), REVENUE CAGR (%), GROSS PROFIT (\BN, $BN), GROSS PROFIT AGR (%) AND GROSS PROFIT CAGR (%), 2011-2018
TABLE 4.61 SUZUKEN: REVENUE (\BN, $BN), REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2016-2018
TABLE 4.62 SUZUKEN: OPERATING INCOME (\BN, $BN), OPERATING INCOME SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2016-2018
TABLE 4.63 SUZUKEN: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
TABLE 4.64 SUZUKEN: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
TABLE 4.65 SUZUKEN: STRATEGIC MOVES & DEVELOPMENTS, 2018-2019
TABLE 4.66 SHANGHAI PHARMACEUTICALS HOLDING: MANAGEMENT MEMBERS, 2018
TABLE 4.67 SHANGHAI PHARMACEUTICALS HOLDING: HISTORICAL REVENUE (RMBBN, $BN), REVENUE AGR (%), REVENUE CAGR (%), 2011-2018
TABLE 4.68 SHANGHAI PHARMACEUTICALS HOLDING: REVENUE (RMBBN, $BN), REVENUE SHARE (%) AND AGR (%) BREAKDOWN BY BUSINESS SEGMENT, 2016-2018
TABLE 4.69 SHANGHAI PHARMACEUTICALS: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2019-2024
TABLE 4.70 SHANGHAI PHARMACEUTICALS: REVENUE ($BN), AGR (%) AND CAGR (%) FORECAST, 2024-2029
TABLE 4.71 MORRIS & DICKSON CO. LLC PROFILE 2018
TABLE 4.72 SMITH DRUG COMPANY, PROFILE 2018
TABLE 4.73 ANDA, INC. PROFILE 2018
TABLE 4.74 CURASCRIPT SPECIALTY DISTRIBUTION. PROFILE 2018
TABLE 4.75 MAWDSLEY-BROOKS & CO. LTD. PROFILE 2018
TABLE 4.76 NORTH CAROLINA MUTUAL WHOLESALE DRUG PROFILE 2018
TABLE 4.77 PRODIGY HEALTH PROFILE 2018
TABLE 4.78 FORTISSA LIMITED PROFILE 2018
TABLE 4.79 CR PHARMACEUTICAL PROFILE 2018
TABLE 4.80 HYGEN PHARMACEUTICALS INC.: PROFILE 2018
TABLE 4.81 FFF ENTERPRISES INC. PROFILE 2018
TABLE 4.82 ROCHESTER DRUG COOPERATIVE, PROFILE 2018
TABLE 4.83 AUBURN PHARMACEUTICAL COMPANY, PROFILE 2018
TABLE 4.84 AUBURN PHARMACEUTICAL COMPANY, GENERIC PRODUCT WITH LAUNCH DATES
TABLE 4.85 CAPITAL WHOLESALE DRUG COMPANY, PROFILE 2018
TABLE 4.86 REALCAN PHARMACEUTICAL GROUP CO., LTD., PROFILE 2018
TABLE 4.87 PROFARMA DISTRIBUIDORA DE PRODUTOS FARMACEUTICOS SA, PROFILE 2018
TABLE 4.88 DAKOTA DRUG, INC., PROFILE 2018
TABLE 4.89 ZHEJIANG INTL GROUP CO., LTD., PROFILE 2018
TABLE 4.90 OHKI HEALTH CARE HOLDINGS, INC., PROFILE 2018
TABLE 4.91 KINGWORLD MEDICINES GROUP LTD., PROFILE 2018
TABLE 5.1 THE PHARMACEUTICAL W&D MARKET: STRENGTHS AND WEAKNESSES
TABLE 5.2 THE PHARMACEUTICAL W&D MARKET: OPPORTUNITIES AND THREATS
TABLE 5.3 STRENGTHS AND WEAKNESSES OF THE DTP DISTRIBUTION MODEL
TABLE 5.4 ITR RATINGS AND CORRESPONDING REIMBURSEMENT RATES, 2018
TABLE 5.5 SOCIAL, TECHNOLOGICAL, ECONOMIC AND POLITICAL FACTORS INFLUENCING THE PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET (STEP ANALYSIS)

List of Figures
FIGURE 2.1 ROUTES OF DRUG DISTRIBUTION, 2018
FIGURE 3.1 THE GLOBAL PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS, 2018
FIGURE 3.2 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN), 2018-2029
FIGURE 3.3 PHARMACEUTICAL WHOLESALE & DISTRIBUTION BY SEGMENT: MARKET SHARES (%), 2018
FIGURE 3.4 PHARMACEUTICAL WHOLESALE & DISTRIBUTION BY SEGMENT: MARKET SHARES (%), 2024
FIGURE 3.5 PHARMACEUTICAL WHOLESALE & DISTRIBUTION BY SEGMENT: MARKET SHARES (%), 2029
FIGURE 3.6 PHARMACEUTICAL WHOLESALE & DISTRIBUTION BY SEGMENT: REVENUE FORECASTS ($BN), 2018-2029
FIGURE 3.7 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS: REVENUE ($BN) FORECAST, 2019-2029
FIGURE 3.8 WHOLESALE AND DISTRIBUTION OF GENERIC DRUGS: REVENUE ($BN) FORECAST, 2018-2029
FIGURE 4.1 MCKESSON: HISTORICAL REVENUE ($BN), REVENUE AGR (%), GROSS PROFIT ($BN) AND GROSS PROFIT AGR (%), 2008-2018
FIGURE 4.2 MCKESSON: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
FIGURE 4.3 MCKESSON: GROSS PROFIT SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
FIGURE 4.4 MCKESSON: REVENUE ($BN) FORECAST, 2019-2029
FIGURE 4.5 MCKESSON: DRIVERS AND RESTRAINTS, 2018
FIGURE 4.6 CARDINAL HEALTH: HISTORICAL REVENUE ($BN), REVENUE AGR (%), OPERATING EARNINGS ($BN) AND OPERATING EARNINGS AGR(%), 2008-2018
FIGURE 4.7 CARDINAL HEALTH: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
FIGURE 4.8 CARDINAL HEALTH: REVENUE SHARE (%) BREAKDOWN BY CUSTOMER, 2018
FIGURE 4.9 CARDINAL HEALTH: REVENUE ($BN) FORECAST, 2019-2029
FIGURE 4.10 CARDINAL HEALTH: DRIVERS AND RESTRAINTS, 2018
FIGURE 4.11 AMERISOURCEBERGEN: HISTORICAL REVENUE ($BN), REVENUE AGR (%), OPERATING INCOME ($BN) AND OPERATING INCOME AGR (%), 2008-2018
FIGURE 4.12 AMERISOURCEBERGEN: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
FIGURE 4.13 AMERISOURCEBERGEN: REVENUE ($BN) BREAKDOWN BY CUSTOMER, 2018
FIGURE 4.14 AMERISOURCEBERGEN: REVENUE ($BN) FORECAST, 2019-2029
FIGURE 4.15 AMERISOURCEBERGEN: DRIVERS AND RESTRAINTS, 2018
FIGURE 4.16 WALGREENS BOOTS ALLIANCE: REVENUE ($BN), REVENUE AGR (%), GROSS PROFIT ($BN) AND GROSS PROFIT AGR (%), 2011-2018
FIGURE 4.17 WALGREENS BOOTS ALLIANCE: REVENUE ($BN) FORECAST, 2019-2029
FIGURE 4.18 WALGREENS BOOTS ALLIANCE: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
FIGURE 4.19 WALGREENS BOOTS ALLIANCE: DRIVERS AND RESTRAINTS, 2018
FIGURE 4.20 MEDIPAL HOLDINGS: HISTORICAL REVENUE (\BN), REVENUE AGR (%), AND GROSS PROFIT AGR (%), 2008-2018
FIGURE 4.21 MEDIPAL HOLDINGS: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
FIGURE 4.22 MEDIPAL HOLDINGS: REVENUE ($BN) FORECAST, 2019-2029
FIGURE 4.23 MEDIPAL HOLDINGS: DRIVERS AND RESTRAINTS, 2018
FIGURE 4.24 PHOENIX GROUP: HISTORICAL REVENUE (£BN), REVENUE AGR (%), GROSS PROFIT (£BN) AND GROSS PROFIT AGR (%), 2011-2018
FIGURE 4.25 PHOENIX GROUP: REVENUE SHARE (%) BREAKDOWN BY REGION, 2018
FIGURE 4.26 PHOENIX GROUP: REVENUE ($BN) FORECAST, 2019-2029
FIGURE 4.27 PHOENIX GROUP DRIVERS AND RESTRAINTS, 2018
FIGURE 4.28 SINOPHARM GROUP: HISTORICAL REVENUE (RMBBN), REVENUE AGR (%), GROSS PROFIT (RMBBN) AND GROSS PROFIT AGR (%), 2011-2018
FIGURE 4.29 SINOPHARM GROUP: REVENUE ($BN) FORECAST, 2019-2029
FIGURE 4.30 SINOPHARM GROUP: DRIVERS AND RESTRAINTS, 2018
FIGURE 4.31 ALFRESA HOLDINGS: HISTORICAL REVENUE (\BN), REVENUE AGR (%), GROSS PROFIT (\BN), GROSS PROFIT AGR (%), 2011-2018
FIGURE 4.32 ALFRESA HOLDINGS: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
FIGURE 4.33 ALFRESA HOLDINGS: REVENUE ($BN) FORECAST, 2019-2029
FIGURE 4.34 ALFRESA HOLDINGS: DRIVERS AND RESTRAINTS, 2018
FIGURE 4.35 SUZUKEN: HISTORICAL REVENUE (\BN), REVENUE AGR (%), GROSS PROFIT (\BN) AND GROSS PROFIT AGR (%), 2011-2018
FIGURE 4.36 SUZUKEN: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
FIGURE 4.37 SUZUKEN: OPERATING INCOME SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
FIGURE 4.38 SUZUKEN: REVENUE ($BN) FORECAST, 2019-2029
FIGURE 4.39 SUZUKEN: DRIVERS AND RESTRAINTS, 2018
FIGURE 4.40 SHANGHAI PHARMACEUTICALS HOLDING: HISTORICAL REVENUE (RMBBN), REVENUE AGR (%), 2011-2018
FIGURE 4.41 SHANGHAI PHARMACEUTICALS HOLDING: REVENUE SHARE (%) BREAKDOWN BY BUSINESS SEGMENT, 2018
FIGURE 4.42 SHANGHAI PHARMACEUTICALS HOLDING: REVENUE ($BN) FORECAST, 2019-2029
FIGURE 4.43 SHANGHAI PHARMACEUTICALS HOLDING: DRIVERS AND RESTRAINTS, 2018
FIGURE 5.1 COMPARISON OF THE WHOLESALE AND DTP ROUTES OF DISTRIBUTION, 2018
FIGURE 6.1 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: GLOBAL MARKET FORECASTS ($BN) BY SUBMARKET, 2019-2029
FIGURE 6.2 LEADING NATIONAL PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKETS: REVENUE PROJECTIONS ($BN), 2018, 2024 AND 2029
FIGURE 6.3 LEADING PHARMACEUTICAL WHOLESALE AND DISTRIBUTION COMPANIES: REVENUE ($BN) PROJECTIONS 2018, 2024 AND 2029

発刊日

2019/06/28

体裁

PDF / 253ページ

販売価格

2,699GBP

発行

Visiongain

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数5人)をご検討ください。
※詳しくはお問い合わせください。

関連カテゴリ

アウトソーシング / 企業

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE